Tumour dormancy: Findings and hypotheses from clinical research on breast cancer

Seminars in Cancer Biology

Volumn 11, Issue 4, 2001, Pages 297-305

  Demicheli, Romano ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Growth models; Metastasis development; Signals from surgery; Tumour dormancy

Indexed keywords

ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER RECURRENCE; CANCER SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; MORTALITY; TREATMENT FAILURE;

EID: 0034865262     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0385     Document Type: Article

References (51)

1. Dynamics of tumor growth
2. Kinetics of tumor growth and regression in IgG multiple myeloma
3. Growth of testicular neoplasm lung metastases: Minor specific relation of between two Gompertzian parameters
4. Growth kinetics of small cell carcinoma of the lung
5. An exponential-Gompertzian description of LoVo cell tumor growth from in-vivo and in-vitro data
6. Local-regional breast cancer recurrence following mastectomy
7. Local recurrences following mastectomy: Support for the concept of tumor dormancy
8. Estimate of tumor growth time for breast cancer local recurrences: Rapid growth after wake-up?
9. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy
10. Comparative analysis of breast cancer recurrence risk for patients receiving adjuvant Cyclophosphamide, Methotrexate, Fluorouracil (CMF). Data supporting the occurrence of "cures"
11. Dormancy of mammary carcinoma after mastectomy
12. Re: Dormancy of mammary carcinoma after mastectomy
13. Rates of growth of pulmonary metastases and host survival
14. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
15. Cancer dormancy: Studies of the murine BCL1 lymphoma
16. A prolactin dependent, metastasising rat mammary carcinoma as a model for endocrine-related tumor dormancy
17. Unusual growth characteristics of human melanoma xenografts in the nude mouse: A model for desmoplasia, dormancy and progression
18. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice
19. Detection and clinical relevance of micrometastatic cancer cells
20. The biology of tumor metastasis
21. Metastasis suppressor genes
22. Molecular mechanisms of cancer metastasis: Tumor and host properties and the role of oncogenes and suppressor genes
23. What is the evidence that tumors are angiogenesis dependent?
24. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells
25. Development of micrometastases: Earliest events detected with bacterial lacz gene-tagged tumor cells
26. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
27. Tumor cell proliferation and sequential chemotherapy after partial tumor resection in C3H/HeJ mammary tumors
28. Effect of surgical removal on the growth and kinetics of residual tumor
29. Presence of a growth-stimulating factor in serum following primary tumor removal in mice
30. Does surgery modify growth kinetics of breast cancer micrometastases?
31. Proposal for a new model of breast cancer metastatic development
32. Induction of angiogenesis during the transition from hyperplasia to neoplasia
33. Computer simulation of a breast cancer metastasis model
34. Systemic treatment of early breast cancer by hormonal cytotoxic, or immune therapy: 133 Randomised trials involving 31000 recurrences and 24000 deaths among 75000 women
35. Surgical adjuvant chemotherapy
36. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer
37. High-dose chemotherapy for primary breast cancer: Facts versus anecdotes
38. Salvage treatments in relapsing resectable breast cancer
39. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy
40. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients
41. Long term follow-up of patients with complete remission following, combination chemotherapy for metastatic breast cancer
42. Variation in the effectiveness of breast screening by year of follow-up
43. Premenopausal status accelerates relapse in node positive breast cancer: Hypothesis links angiogenesis, screening controversy
44. Vascular endothelial growth factor in premenopausal women-indicator of the best time for breast cancer surgery?
45. Menstrual influence on surgical cure of breast cancer
46. Menstrual timing of breast cancer surgery
47. Shifting the cancer paradigm: Must we kill to cure?
48. Tumor vasculature as a target for anticancer therapy
49. Herceptin (trastuzamab) in advanced breast cancer
50. Cancer dormancy: Opportunities for new therapeutic approaches